Please enable JavaScript to continue using this application.

Compare $FHTX vs $GNLX | Chartloom

Compare

$FHTX vs $GNLX

Foghorn Therapeutics Inc · Genelux Corp

FHTX

Foghorn Therapeutics Inc

GNLX

Genelux Corp

Compare $FHTX vs $GNLX

Comparing Foghorn Therapeutics Inc and Genelux Corp

FHTXFoghorn Therapeutics Inc

GNLXGenelux Corp

FHTXFoghorn Therapeutics Inc

Market cap

$117M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

4.04x

Rev growth (TTM)

52.0%

YTD performance

-61.5%

52W performance

-55.6%

FCF yield

-71.8%

GNLXGenelux Corp

Market cap

$115M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-43.7%

52W performance

-46.1%

FCF yield

-25.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

FHTX

GNLX

Detailed metrics comparison

FHTX

Foghorn Therapeutics Inc

GNLX

Genelux Corp

Market Cap

FHTX$117M

GNLX$115M

Enterprise Value

FHTX$49M

GNLX$106M

Price

FHTX$2.00

GNLX$2.56

P/E Ratio

FHTXN/A

GNLXN/A

P/S Ratio

FHTX3.20x

GNLX14,348.80x

EV/Sales

FHTX1.34x

GNLX13,200.80x

EV/EBITDA

FHTX0.00x

GNLX0.00x

P/B Ratio

FHTX1,199.58x

GNLX7.19x

P/FCF Ratio

FHTXN/A

GNLXN/A

EV/FCF

FHTX-0.59x

GNLX-3.68x

PEG Ratio

FHTXN/A

GNLXN/A

Forward P/E (NTM)

FHTXN/A

GNLXN/A

Forward P/S (NTM)

FHTX4.04x

GNLXN/A

Revenue (TTM)

FHTX$37M

GNLX$8K

Revenue Growth (YoY)

FHTX52.0%

GNLXN/A

Forward Rev Growth

FHTX7.3%

GNLX551.6%

Gross Margin (TTM)

FHTX0.0%

GNLX0.0%

Operating Margin (TTM)

FHTX0.0%

GNLX0.0%

EBITDA Margin (TTM)

FHTX-180.6%

GNLX-453500.0%

Net Margin (TTM)

FHTX-175.8%

GNLX-444950.0%

FCF Margin (TTM)

FHTX-229.4%

GNLX-358537.5%

Net Income (TTM)

FHTX$-65M

GNLX$-36M

FCF (TTM)

FHTX$-84M

GNLX$-29M

EPS (TTM)

FHTX-$0.91

GNLX-$0.79

ROE (TTM)

FHTX-30161.0%

GNLX-20585.0%

ROA (TTM)

FHTX-3117.0%

GNLX-13879.0%

ROIC (TTM)

FHTX-30161.0%

GNLX-20585.0%

Cash

FHTX$68M

GNLX$9M

Debt

FHTX$0

GNLX$0

Net Cash/Debt

FHTX$68M

GNLX$9M

Current Ratio (TTM)

FHTX3.36x

GNLX2.39x

Quick Ratio (TTM)

FHTX3.31x

GNLX2.33x

Debt/Equity (TTM)

FHTX0.00x

GNLX0.00x

Debt/Assets (TTM)

FHTX0.0%

GNLX0.0%

Interest Coverage (TTM)

FHTXN/A

GNLXN/A

Net Debt/EBITDA (TTM)

FHTX0.00x

GNLX0.00x

Beta

FHTX3.13

GNLX0.56

52W Performance

FHTX-55.6%

GNLX-46.1%

YTD Performance

FHTX-61.5%

GNLX-43.7%

% from 52W High

FHTX-73.7%

GNLX-70.0%

% from 52W Low

FHTX11.7%

GNLX11.8%

Asset Turnover (TTM)

FHTX0.18x

GNLX0.00x

FCF Yield (TTM)

FHTX-71.8%

GNLX-25.0%

Earnings Yield (TTM)

FHTX-55.0%

GNLX-31.0%

Dividend Yield (TTM)

FHTXN/A

GNLXN/A

Rule of 40

FHTX-177.4

GNLX-358,537.5

EV/GP/RG

FHTXN/A

GNLXN/A

Ticker research

View FHTX research View GNLX research

Metric	FHTX Foghorn Therapeutics Inc	GNLX Genelux Corp
Market & Valuation
Market Cap	$117M	$115M
Enterprise Value	$49M	$106M
Price	$2.00	$2.56
P/E Ratio	N/A	N/A
P/S Ratio	3.20x	14,348.80x
EV/Sales	1.34x	13,200.80x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1,199.58x	7.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.59x	-3.68x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.04x	N/A
Revenue & Growth
Revenue (TTM)	$37M	$8K
Revenue Growth (YoY)	52.0%	N/A
Forward Rev Growth	7.3%	551.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-180.6%	-453500.0%
Net Margin (TTM)	-175.8%	-444950.0%
FCF Margin (TTM)	-229.4%	-358537.5%
Net Income (TTM)	$-65M	$-36M
FCF (TTM)	$-84M	$-29M
EPS (TTM)	-$0.91	-$0.79
ROE (TTM)	-30161.0%	-20585.0%
ROA (TTM)	-3117.0%	-13879.0%
ROIC (TTM)	-30161.0%	-20585.0%
Financial Health
Cash	$68M	$9M
Debt	$0	$0
Net Cash/Debt	$68M	$9M
Current Ratio (TTM)	3.36x	2.39x
Quick Ratio (TTM)	3.31x	2.33x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.13	0.56
52W Performance	-55.6%	-46.1%
YTD Performance	-61.5%	-43.7%
% from 52W High	-73.7%	-70.0%
% from 52W Low	11.7%	11.8%
Efficiency & Yields
Asset Turnover (TTM)	0.18x	0.00x
FCF Yield (TTM)	-71.8%	-25.0%
Earnings Yield (TTM)	-55.0%	-31.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-177.4	-358,537.5
EV/GP/RG	N/A	N/A
Ticker research	View FHTX research	View GNLX research

Valuation

P/S Ratio

FHTX

3.20x

GNLX

14,348.80x

EV/FCF

GNLX

-3.68x

FHTX

-0.59x

Growth & revenue

Revenue Growth TTM

FHTX

52.0%

Forward Revenue Growth

GNLX

551.6%

FHTX

7.3%

Profitability & performance

Gross Margin

FHTX

0.0%

GNLX

0.0%

ROE

GNLX

-20585.0%

FHTX

-30161.0%

FCF Yield %

GNLX

-25.0%

FHTX

-71.8%

52-Week Performance

GNLX

-46.1%

FHTX

-55.6%

Detailed metrics comparison

FHTX

Foghorn Therapeutics Inc

GNLX

Genelux Corp

Market Cap

FHTX$117M

GNLX$115M

Enterprise Value

FHTX$49M

GNLX$106M

Price

FHTX$2.00

GNLX$2.56

P/E Ratio

FHTXN/A

GNLXN/A

P/S Ratio

FHTX3.20x

GNLX14,348.80x

EV/Sales

FHTX1.34x

GNLX13,200.80x

EV/EBITDA

FHTX0.00x

GNLX0.00x

P/B Ratio

FHTX1,199.58x

GNLX7.19x

P/FCF Ratio

FHTXN/A

GNLXN/A

EV/FCF

FHTX-0.59x

GNLX-3.68x

PEG Ratio

FHTXN/A

GNLXN/A

Forward P/E (NTM)

FHTXN/A

GNLXN/A

Forward P/S (NTM)

FHTX4.04x

GNLXN/A

Revenue (TTM)

FHTX$37M

GNLX$8K

Revenue Growth (YoY)

FHTX52.0%

GNLXN/A

Forward Rev Growth

FHTX7.3%

GNLX551.6%

Gross Margin (TTM)

FHTX0.0%

GNLX0.0%

Operating Margin (TTM)

FHTX0.0%

GNLX0.0%

EBITDA Margin (TTM)

FHTX-180.6%

GNLX-453500.0%

Net Margin (TTM)

FHTX-175.8%

GNLX-444950.0%

FCF Margin (TTM)

FHTX-229.4%

GNLX-358537.5%

Net Income (TTM)

FHTX$-65M

GNLX$-36M

FCF (TTM)

FHTX$-84M

GNLX$-29M

EPS (TTM)

FHTX-$0.91

GNLX-$0.79

ROE (TTM)

FHTX-30161.0%

GNLX-20585.0%

ROA (TTM)

FHTX-3117.0%

GNLX-13879.0%

ROIC (TTM)

FHTX-30161.0%

GNLX-20585.0%

Cash

FHTX$68M

GNLX$9M

Debt

FHTX$0

GNLX$0

Net Cash/Debt

FHTX$68M

GNLX$9M

Current Ratio (TTM)

FHTX3.36x

GNLX2.39x

Quick Ratio (TTM)

FHTX3.31x

GNLX2.33x

Debt/Equity (TTM)

FHTX0.00x

GNLX0.00x

Debt/Assets (TTM)

FHTX0.0%

GNLX0.0%

Interest Coverage (TTM)

FHTXN/A

GNLXN/A

Net Debt/EBITDA (TTM)

FHTX0.00x

GNLX0.00x

Beta

FHTX3.13

GNLX0.56

52W Performance

FHTX-55.6%

GNLX-46.1%

YTD Performance

FHTX-61.5%

GNLX-43.7%

% from 52W High

FHTX-73.7%

GNLX-70.0%

% from 52W Low

FHTX11.7%

GNLX11.8%

Asset Turnover (TTM)

FHTX0.18x

GNLX0.00x

FCF Yield (TTM)

FHTX-71.8%

GNLX-25.0%

Earnings Yield (TTM)

FHTX-55.0%

GNLX-31.0%

Dividend Yield (TTM)

FHTXN/A

GNLXN/A

Rule of 40

FHTX-177.4

GNLX-358,537.5

EV/GP/RG

FHTXN/A

GNLXN/A

Ticker research

View FHTX research View GNLX research

Metric	FHTX Foghorn Therapeutics Inc	GNLX Genelux Corp
Market & Valuation
Market Cap	$117M	$115M
Enterprise Value	$49M	$106M
Price	$2.00	$2.56
P/E Ratio	N/A	N/A
P/S Ratio	3.20x	14,348.80x
EV/Sales	1.34x	13,200.80x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1,199.58x	7.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.59x	-3.68x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.04x	N/A
Revenue & Growth
Revenue (TTM)	$37M	$8K
Revenue Growth (YoY)	52.0%	N/A
Forward Rev Growth	7.3%	551.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-180.6%	-453500.0%
Net Margin (TTM)	-175.8%	-444950.0%
FCF Margin (TTM)	-229.4%	-358537.5%
Net Income (TTM)	$-65M	$-36M
FCF (TTM)	$-84M	$-29M
EPS (TTM)	-$0.91	-$0.79
ROE (TTM)	-30161.0%	-20585.0%
ROA (TTM)	-3117.0%	-13879.0%
ROIC (TTM)	-30161.0%	-20585.0%
Financial Health
Cash	$68M	$9M
Debt	$0	$0
Net Cash/Debt	$68M	$9M
Current Ratio (TTM)	3.36x	2.39x
Quick Ratio (TTM)	3.31x	2.33x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.13	0.56
52W Performance	-55.6%	-46.1%
YTD Performance	-61.5%	-43.7%
% from 52W High	-73.7%	-70.0%
% from 52W Low	11.7%	11.8%
Efficiency & Yields
Asset Turnover (TTM)	0.18x	0.00x
FCF Yield (TTM)	-71.8%	-25.0%
Earnings Yield (TTM)	-55.0%	-31.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-177.4	-358,537.5
EV/GP/RG	N/A	N/A
Ticker research	View FHTX research	View GNLX research